Role of Bispecifics and Future Promising Treatments in DLBCL
Shared excitement for bispecific antibodies and other promising novel therapies in the treatment of patients with DLBCL.
The Future of DLBCL Treatment
A look at exciting investigational agents and clinical trials for patients with relapsed/refractory diffuse large B-cell lymphoma.
Management and Work-up of Patients for Salvage Therapy
The panelists share their approach to the treatment and work-up of patients who require salvage therapy.
Strategies for Supportive Care and Monitoring in Patients Who Have Received CAR T-Cell Therapy
Experts in lymphoma take part in a discussion on supportive care for patients who receive CAR T-cell therapy.
A Closer Look at CAR T-Cell Therapy Clinical Trial Design
Subject matter experts in lymphoma reflect on chimeric antigen receptor T-cell therapy clinical trial design.
Clinical Trials Evaluating CAR T-Cell Therapies in Second-Line Treatment of Patients With DLBCL
Frederick Locke, MD, provides an in-depth look at data from 3 clinical trials investigating chimeric antigen receptor T-cell therapy in the second-line treatment of diffuse large B-cell lymphoma.
Therapeutic Sequencing and Bridging in DLBCL
Optimizing approaches to therapeutic sequencing in relapsed/refractory DLBCL.
Treating Patients Who Relapse or Progress on CAR T-Cell Therapy
Drs Nowakowski and Gordon discuss treatment options after disease relapse on CAR T-cell therapy.
A Closer Look at the Potential Impact of Bispecific Antibodies on the DLBCL Treatment Landscape
Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.
Comparing Real-World Evidence With Data From Clinical Trials
The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.
Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL
Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.
Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL
Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.
Improving Outcomes in Patients With DLBCL
Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.
A Focus on Frontline Treatment in Patients With DLBCL
Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.
Clinical Pearls in the Management of Marginal Zone Lymphoma
Closing out their discussion on B-cell malignancies, expert panelists share clinical pearls on the management of marginal zone lymphoma.
Novel Treatment Strategies for Relapsed/Refractory MZL
A comprehensive review of novel therapies in relapsed/refractory marginal zone lymphoma and possible sequencing strategies in this setting.
Frontline Treatment Options for Marginal Zone Lymphoma
Shared insight on frontline treatment approaches for patients diagnosed with marginal zone lymphoma.
Clinical Pearls in the Management of Follicular Lymphoma
Clinical pearls for community physicians regarding the optimal management of patients with follicular lymphoma.
Optimizing the Sequencing of Therapy in Follicular Lymphoma
Panelists use an illustrative clinical case to comprehensively discuss the selection and sequencing of therapies for patients with follicular lymphoma.
PI3K Inhibitors in Relapsed/Refractory Follicular Lymphoma
A review of the role of PI3K inhibitors in the treatment of follicular lymphoma, and how they have been used to improve patient outcomes.
Black Women With HR+ Breast Cancer Have Worse Outcomes, Despite Similar Recurrence Scores
Benefit of Adjuvant Abemaciclib Increases at 4-Year monarchE Landmark Analysis for Patients With HR+/HER2– High-Risk Early Breast Cancer
Everolimus Plus Adjuvant Endocrine Therapy Fails to Improve iDFS, OS in HR+/HER2- Breast Cancer
Frontline Ribociclib Plus Endocrine Therapy Provides PFS Benefit in Pre/Perimenopausal HR+/HER2- Advanced Breast Cancer
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.